Stocks Health care OVID
NASDAQ · Health careOvid Therapeutics Inc. (OVID)
Ovid Therapeutics Inc. brought in $1.6M of revenue over the twelve months to June 30, 2026, down 76.2% from a year earlier. It posted a net loss of $34.5M. In fiscal 2025 capital spending exceeded operating cash flow by $38.3M. At June 30, 2026 it held $11.3M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
Key facts about Ovid Therapeutics Inc.
- Net worth
- Ovid Therapeutics Inc. has a market value (market cap) of $554.5M at the latest share price, and shareholders' equity of $209.9M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $7.3M (+1,181.3% year on year), with a net loss of $17.4M. Over the 12 months to June 30, 2026: revenue $1.6M, net loss $34.5M.
- Cash flow
- In fiscal 2025 operations used $38.3M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 13, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
What Ovid Therapeutics Inc. does
Ovid Therapeutics Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker OVID.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $7.3M | -$17.4M | n/a | -$38.3M |
| 2024 | $566K | -$26.4M | n/a | -$56M |
| 2023 | $392K | -$52.3M | -$0.74 | -$45.8M |
| 2022 | $1.5M | -$54.2M | -$0.77 | -$56.5M |
| 2021 | $208.4M | $122.8M | $1.76 | $118.4M |
| 2020 | $12.6M | -$81M | -$1.39 | -$51.7M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where OVID ranks in Health care
Latest SEC filings
What Ovid Therapeutics Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 88% to $733K versus the same quarter last year; net loss of $15M.
- August 13, 2026Exhibits 8-K
- July 29, 2026Passive stake (5% or more) SCHEDULE 13G
- July 8, 2026
- June 11, 2026
Insider trades
What the people running Ovid Therapeutics Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| July 6, 2026 | Carter Charles RossChief Financial Officer | Received as pay | 50,000 | - |
| April 7, 2026 | Papadopoulos SteliosDirector | Received as pay | 17,578 | $45K |
| April 7, 2026 | Friedman BartDirector | Received as pay | 8,789 | $22.5K |
| April 7, 2026 | Fitzgerald Kevin JosephDirector | Received as pay | 17,578 | $45K |
| March 23, 2026 | Levin Jeremy MExecutive Chairman, Director | Exercised options | 47,333 | $66.3K |
| February 26, 2026 | Rona Jeffrey ACBFO | Received as pay | 68,125 | - |
| February 23, 2026 | Rona Jeffrey ACBFO | Sold | 8,541 | $12.4K |
| February 23, 2026 | Alexander Margaret A.President and CEO, Director | Sold | 11,656 | $16.9K |
Who owns OVID
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Janus Henderson Group PLC13G, passive | 9.99% | December 8, 2025 |
| RA Capital Management, L.P.13G, passive with 3 related filers | 9.9% | August 14, 2026 |
| Sirenia Capital Management LP13G, passive with 1 related filers | 9.9% | May 15, 2026 |
| Affinity Asset Advisors, LLC13G, passive with 1 related filers | 7.9% | August 13, 2026 |
| Eventide Asset Management, LLC13G, passive with 2 related filers | 6.3% | August 14, 2026 |
| ADAR1 Capital Management, LLC13G, passive with 2 related filers | 5.1% | August 14, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 131 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Jupiter Topco LLC | 20,741,234 | new |
| Eventide Asset Management, LLC | 11,812,241 | +1,895,330 |
| BlackRock, Inc. | 10,823,480 | +9,290,197 |
| RA Capital Management, L.P. | 10,500,968 | -213,032 |
| Affinity Asset Advisors, LLC | 10,144,562 | -491,756 |
| State Street Corp | 7,900,765 | +7,380,482 |
| Vanguard Capital Management LLC | 7,760,114 | +2,501,868 |
| ADAR1 Capital Management, LLC | 7,417,479 | +2,873,366 |
| Balyasny Asset Management L.P. | 6,719,076 | +1,186,003 |
| Adage Capital Partners GP, L.L.C. | 6,163,781 | 0 |
| Federated Hermes, Inc. | 5,951,666 | +2,380,666 |
| Braidwell LP | 5,919,464 | new |
| Geode Capital Management, LLC | 4,072,653 | +2,754,562 |
| Silverarc Capital Management, LLC | 3,101,129 | +2,101,129 |
| Stempoint Capital LP | 2,417,283 | new |
| Ikarian Capital, LLC | 2,269,704 | -625,000 |
| Point72 Asset Management, L.P. | 1,945,727 | +625,117 |
| Sphera Funds Management Ltd. | 1,353,000 | -269,828 |
| Northern Trust Corp | 1,246,139 | +991,335 |
| Vanguard Fiduciary Trust Co | 1,140,753 | +447,497 |
Insiders
8 insiders reported holding 11,291,431 shares in total, about $32.1M at the last price.
| Holder | Shares |
|---|---|
| Takeda Pharmaceutical Co Ltd10% owner | 7,000,0007,000,000 held indirectly |
| Levin Jeremy MExecutive Chairman, Director | 3,735,048 |
| Papadopoulos SteliosDirector | 217,578 |
| Rona Jeffrey ACBFO | 156,313 |
| Carter Charles RossChief Financial Officer | 94,375 |
| Alexander Margaret A.President and CEO, Director | 61,750 |
| Fitzgerald Kevin JosephDirector | 17,578 |
| Friedman BartDirector | 8,789 |
Questions about OVID
What does Ovid Therapeutics Inc. do?
Ovid Therapeutics Inc. is a company in the Health care sector, listed on NASDAQ as OVID. Its shares trade on NASDAQ under the ticker OVID.
What is Ovid Therapeutics Inc.'s net worth?
Ovid Therapeutics Inc. has a market value (market cap) of $554.5M at the latest share price, and shareholders' equity of $209.9M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Ovid Therapeutics Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $34.5M on revenue of $1.6M.
How much revenue does Ovid Therapeutics Inc. make?
Over the twelve months to June 30, 2026 Ovid Therapeutics Inc. reported revenue of $1.6M. That is 76.2% less than a year earlier.
When did Ovid Therapeutics Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the planned insider sale from August 24, 2026.
Similar companies
Compare OVID with
Follow OVID
Get an email when Ovid Therapeutics Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Ovid Therapeutics Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.